Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell Interplay
dc.contributor.author | Luz-Crawford, Patricia | |
dc.contributor.author | Espinosa-Carrasco, Gabriel | |
dc.contributor.author | Ipseiz, Natacha | |
dc.contributor.author | Contreras, Rafael | |
dc.contributor.author | Tejedor, Gautier | |
dc.contributor.author | Medina, Daniel A. | |
dc.contributor.author | Vega-Letter, Ana-Maria | |
dc.contributor.author | Ngo, Devi | |
dc.contributor.author | Morand, Eric F. | |
dc.contributor.author | Pene, Jerome | |
dc.contributor.author | Hernandez, Javier | |
dc.contributor.author | Jorgensen, Christian | |
dc.contributor.author | Djouad, Farida | |
dc.date.accessioned | 2025-01-23T21:22:37Z | |
dc.date.available | 2025-01-23T21:22:37Z | |
dc.date.issued | 2018 | |
dc.description.abstract | Mesenchymal stem cells (MSC) are highly immunosuppressive cells able to reduce chronic inflammation through the active release of mediators. Recently, we showed that glucocorticoid-induced leucine zipper (Gilz) expression by MSC is involved in their therapeutic effect by promoting the generation of regulatory T cells. However, the mechanisms underlying this pivotal role of Gilz remain elusive. | |
dc.description.abstract | Methods and Results In this study, we have uncovered evidence that Gilz modulates the phenotype and function of Th1 and Th17 cells likely by upregulating the level of Activin A and NO2 secreted by MSC. Adoptive transfer experiments sustained this Gilz-dependent suppressive effect of MSC on Th1 and Th17 cell functions. In immunoregulatory MSC, obtained by priming with IFN-gamma and TNF-alpha, Gilz was translocated to the nucleus and bound to the promoters of inos and Activin beta A to induce their expression. The increased expression of Activin A directly impacted on Th17 cells fate by repressing their differentiation program through the activation of Smad3/2 and enhancing IL-10 production. | |
dc.description.abstract | Conclusion Our results reveal how Gilz controls inos and Activin beta A gene expression to ultimately assign immunoregulatory status to MSC able to repress the pathogenic Th17 cell differentiation program and uncover Activin A as a novel mediator of MSC in this process. | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.7150/thno.21793 | |
dc.identifier.issn | 1838-7640 | |
dc.identifier.uri | https://doi.org/10.7150/thno.21793 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/101259 | |
dc.identifier.wosid | WOS:000435598500010 | |
dc.issue.numero | 3 | |
dc.language.iso | en | |
dc.pagina.final | 859 | |
dc.pagina.inicio | 846 | |
dc.revista | Theranostics | |
dc.rights | acceso restringido | |
dc.subject | Mesenchymal Stem Cells | |
dc.subject | Gilz | |
dc.subject | Activin A | |
dc.subject | Th17 cells | |
dc.subject | Immunosuppression | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Gilz-Activin A as a Novel Signaling Axis Orchestrating Mesenchymal Stem Cell and Th17 Cell Interplay | |
dc.type | artículo | |
dc.volumen | 8 | |
sipa.index | WOS | |
sipa.trazabilidad | WOS;2025-01-12 |